Drug General Information (ID: DDIZ2C5LJ3)
Drug Name			Bexarotene		Drug Info		Zalcitabine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Anti-Hiv Agents
Structure

Mechanism of Bexarotene-Zalcitabine Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Bexarotene				Zalcitabine
Mechanism		Pancreatic toxicity				Pancreatic toxicity
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Bexarotene and Zalcitabine

Recommended Action
Management		Caution is advised when bexarotene is given in combination with other medications that are known to increase triglyceride levels or associated with pancreatic toxicity. Other risk factors such as a history of pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, or biliary tract disease should also be considered when weighing benefits versus risks of bexarotene therapy. All patients treated with bexarotene should have fasting blood lipids measured before initiating therapy, weekly during therapy until the lipid response to bexarotene is established (usually within two to four weeks), and at 8-week intervals thereafter.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.